Roche Reveals Development Strategies In China
This article was originally published in PharmAsia News
Shanghai Roche Pharmaceuticals CEO Zhou Ping-Shan has revealed the company's development plans in China in a recent interview. First is focus: Roche enjoys a leading position in such key therapeutic areas as oncology, virology and transplant by relying on its strong R&D and innovative capability. It is committed to promoting local pharmaceutical industry innovation and has set up an R&D center as well as a pharmaceutical development center. Second is the company's emphasis on collaboration with the Chinese biopharmaceutical industry. Roche has built up close partnerships with local universities, academic institutions and biopharmaceutical enterprises. Zhou notes that pharmaceutical enterprises must adapt rapidly to China's policy and reform as the nation's health care is in a revolutionary stage. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.